Research graph
References from Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). Local targets link to admitted publications; unresolved targets remain external evidence.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
10.1016/s1470-2045(21)00098-x · 2021 · External reference
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - pooled analysis from the PRIMA trial
10.1016/j.ygyno.2022.06.028 · 2022 · External reference
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
10.1056/nejmoa1911361 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
10.1016/j.annonc.2023.05.005 · 2023 · External reference
Unresolved reference
External reference
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
10.1093/jnci/85.5.365 · 1993 · External reference
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer
10.1016/s0959-8049(03)00307-1 · 2003 · External reference
Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group Experience
10.1111/j.1524-4733.2007.00278.x · 2007 · External reference
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · 2018 · External reference
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
10.1016/j.ygyno.2021.07.016 · 2021 · External reference
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
10.1016/j.ygyno.2024.01.021 · 2024 · External reference
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
10.1016/s1470-2045(19)30790-9 · 2020 · External reference
Evaluation of scores to reflect toxicity impact on quality of life of patients with platinum-resistant ovarian cancer: AURELIA substudy
10.6004/jnccn.2022.7101 · 2023 · External reference
Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II)
10.1200/jco.2022.40.16_suppl.e17609 · 2022 · External reference
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
10.1093/annonc/mds494 · 2013 · External reference
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
10.1200/jco.2013.50.5669 · 2014 · External reference
Digital solutions supporting the quality-of-life of European cancer patients and their caregivers: a systematic literature review
10.1007/s12553-025-00942-2 · 2025 · External reference
Fatigue trajectories by wearable remote monitoring of breast cancer patients during radiotherapy
10.1038/s41598-024-78805-5 · 2024 · External reference
European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and industry partners—first update 2015
10.1097/igc.0000000000000478 · 2015 · External reference
European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and pharmaceutical companies
10.1111/igc.0b013e3181d3caa8 · 2010 · External reference
